Browse studies, page 1089
Page 1089 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study Journal of Diabetes Research, 2024
- Type Disparity in Sodium–Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study Cancers, 2024
- The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Transthyretin Cardiac Amyloidosis: A Single-Center Retrospective Cohort Study Cureus, 2024
- Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study BMC Endocrine Disorders, 2025
- The Role of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Sarcoid Cardiomyopathy: A Multicenter Retrospective Cohort Study American Journal of Cardiovascular Drugs, 2025
- Effects of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and nonalcoholic fatty liver disease: A cohort study Saudi Pharmaceutical Journal, 2025
- Personalized Response to Empagliflozin in Heart Failure: Association of BDNF and ATP2A2 Variants in a South Asian Cohort Biomedicines, 2025
- Outcomes of Patients With Autosomal Dominant Polycystic Kidney Disease Prescribed SGLT2 Inhibitors in British Columbia: A Single-Arm Retrospective Cohort Study Canadian Journal of Kidney Health and Disease, 2025
- The effect of empagliflozin on the quality of life in patients with heart failure: results from the Hungarian cohort of the international Emp-Activity study Orvosi Hetilap, 2026
- 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study EClinicalMedicine, 2024
- Cardiorenal outcomes of empagliflozin versus dapagliflozin in primary prevention among patients with type 2 diabetes: A nationwide cohort study Diabetes Research and Clinical Practice, 2026
- Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study Cardiovascular Diabetology, 2019
- Association of empagliflozin treatment with changes in the metabolic score for insulin resistance in Iraqi adults with type 2 diabetes: a 6-month prospective cohort study International Journal of Basic & Clinical Pharmacology, 2026
- CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study) Clinical drug investigation, 2022
- Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea Pharmaceutics, 2023
- Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study Saudi Pharmaceutical Journal, 2023
- Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study Cardiovascular Diabetology, 2023
- Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study European Heart Journal, 2024
- Comparative outcomes between empagliflozin and dapagliflozin in heart failure: real world multi-center cohort study European Heart Journal, 2024
- Evaluation of Rehospitalization Rate in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Treated with Empagliflozin in Saudi Arabia: A Single-Center Retrospective Cohort Study Saudi Journal of Clinical Pharmacy, 2024
- Assessing Renoprotective Effects of Empagliflozin and Telmisartan Combination Therapy in Non-albuminuric Diabetic Nephropathy: A Retrospective Cohort Study Cureus, 2025
- Comparative Long-Term Cardiovascular Outcomes of Empagliflozin and Dapagliflozin in Heart Failure Patients After Coronary Revascularization: A Retrospective Cohort Study Journal of Clinical Medicine, 2025
- Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18) Cureus, 2025
- Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study European Heart Journal, 2025
- Impact of Empagliflozin on Cardiovascular Outcomes and Renal Function in Patients with Obesity and Type 2 Diabetes: A Retrospective Cohort Study Diabetes Therapy, 2025
- Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Medical Science, 2025
- Use of SGLT2 Inhibitors Versus DPP-4 Inhibitors and Age-Related Macular Degeneration in Patients WithType 2 Diabetes: A Multinational Cohort Study Investigative ophthalmology & visual science, 2025
- Investigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes - Results From the EMPYREAN Study Circulation journal : official journal of the Japanese Circulation Society, 2025
- Cognitive impairment in young and middle-aged patients with acute heart failure ESC heart failure, 2024
- Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics Diabetes care, 2020
- Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known? American journal of therapeutics, 2020
- Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®. Diabetes & vascular disease research, 2020
- Impact of Empagliflozin Versus Dapagliflozin on Left Ventricular Remodeling in Heart Failure Patients: A 1-Year Comparative Study Clinical cardiology, 2025
- SGLT2 inhibitors, new option to prevent or treat heart failure Revue medicale de Liege, 2021
- Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus Endocrinology and metabolism (Seoul, Korea), 2021
- Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease Frontiers in endocrinology, 2025
- Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program Journal of the American College of Cardiology, 2024
- Effects of sodium-glucose co-transporter-2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes: A multi-institutional cohort study Diabetes, obesity & metabolism, 2020
- Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States Diabetes, obesity & metabolism, 2022
- SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis JAMA network open, 2026
- Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data Diabetes, obesity & metabolism, 2025
- The real-world anti-inflammatory effect of SGLT2i in patients with chronic heart failure Journal of medicine and life, 2025
- Application of eligibility criteria from DAPA-HF, EMPEROR-Reduced, and PARADIGM-HF trials to a population with heart failure with reduced ejection fraction at a specialized cardiology Clinic in Medellin, Colombia: A retrospective cohort study Current problems in cardiology, 2024
- Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure ESC heart failure, 2022
- Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population International journal of cardiology, 2025
- Treatment outcomes of graded dose of empagliflozin in type-2 diabetes: A real world study Annals of African medicine, 2022
- Shifting Towards Empagliflozin First-Line Therapy in Glycogen Storage Disease Type Ib: A Nationwide Real-World Study Journal of inherited metabolic disease, 2026
- Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes JAMA network open, 2025
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic and Non-Diabetic Patients with Advanced Chronic Kidney Disease in Peritoneal Dialysis on Residual Kidney Function: In Real-World Data Medicina (Kaunas, Lithuania), 2024
- Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study Diabetes & vascular disease research, 2020
- Systolic blood pressure at admission and long-term clinical outcomes in patients hospitalized for heart failure ESC heart failure, 2021
- Management of sodium-glucose cotransporter 2 inhibitors during the perioperative period: A retrospective comparative study Journal of perioperative practice, 2021
- Discharge heart rate and 1-year clinical outcomes in heart failure patients with atrial fibrillation Chinese medical journal, 2022
- Healthy lifestyle behaviours and all-cause and cardiovascular mortality among 0.9 million Chinese adults The international journal of behavioral nutrition and physical activity, 2021
- Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2 Medicina clinica, 2019
- Dapagliflozin vs. Empagliflozin for cardiorenal risk reduction: Real-world paired data and comparative study in Indonesia . F1000Research, 2025
- Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis Circulation, 2024
- Efficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study Kardiologiia, 2025
- Changes in ST segment elevation myocardial infarction hospitalisations in China from 2011 to 2015 Open heart, 2021
- The evaluation of noninferiority for renal composite outcomes between sodium-glucose cotransporter inhibitors in Japan Primary care diabetes, 2021
- Empagliflozin and hydralazine-isosorbide dinitrate combination therapy improves outcomes in Black patients with heart failure International journal of clinical pharmacology and therapeutics, 2025
- Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study Annals of internal medicine, 2024
- Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors Journal of diabetes and its complications, 2019
- Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm Texas Heart Institute journal, 2023
- The short-term follow-up of patients with diabetes mellitus presenting with COVID-19 Journal of medicine and life, 2025
- Mechanism and reversal of drug-induced nephrotoxicity on a chip Science translational medicine, 2021
- SGLT2 Inhibitors Decrease Overhydration and Proteasuria in Patients with Chronic Kidney Disease: A Longitudinal Observational Study Kidney & blood pressure research, 2024
- Rationale and design of the EMPYREAN study ESC heart failure, 2020
- Solution is not simple; sodium-glucose cotransporter-2 inhibitor use in Conn syndrome Blood pressure monitoring, 2024
- Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study Diabetes, obesity & metabolism, 2018
- Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes Diabetes, 2021
- Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study Circulation. Heart failure, 2021
- Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus Journal of primary care & community health, 2019
- Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation Diabetes, obesity & metabolism, 2026
- Empagliflozin and Dapagliflozin Outcomes in Heart Failure JAMA network open, 2025
- The position of SGLT2 inhibitors in current medicine Vnitrni lekarstvi, 2020
- Impact of SGLT2 Inhibitors Use on Risk of Postoperative Acute Kidney Injury Following Metabolic and Bariatric Surgery: A Retrospective Study Obesity surgery, 2025
- Metabolic Profiling of the EmDia Cohort by LC-MS Reveals Empagliflozin-Intake Associated Regulation of 1,5-anhydroglucitol and Urate Proteomics, 2026
- Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study Diabetes care, 2023
- Association of liver fibrosis with cognitive test performance and brain imaging parameters in the UK Biobank study Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023
- Impact of Predischarge NT-proBNP on Treatment Optimisation in Acute Heart Failure International journal of molecular sciences, 2026
- Cardiac mechanics and incident ischemic stroke: the Cardiovascular Health Study Scientific reports, 2021
- Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus Liver international : official journal of the International Association for the Study of the Liver, 2025
- Relationship of concomitant anti-diabetic drug administration with sodium-glucose co-transporter 2 inhibitor-related ketosis The Journal of international medical research, 2022
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study The lancet. Diabetes & endocrinology, 2020
- Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi-Bickel syndrome with empagliflozin Journal of inherited metabolic disease, 2024
- Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study Diabetes research and clinical practice, 2019
- Empagliflozin in heart failure with preserved ejection fraction: from randomized trials to real-world evidence Acta cardiologica, 2025
- Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study PloS one, 2025
- Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study Scientific reports, 2025
- SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study BMJ (Clinical research ed.), 2024
- Semaglutide and diabetic retinopathy: an OHDSI network study BMJ open diabetes research & care, 2025
- Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Observational Evidence in Geriatric Patients-AGING-HF. Circulation. Heart failure, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy JAMA ophthalmology, 2025
- Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial EClinicalMedicine, 2025
- Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers? Biomarkers, 2021
- Perceived Barriers to SGLT2i Prescription in Primary Care vs. Nephrology Providers: Findings From the Michigan Kidney Improvement Collaborative Journal of the American Society of Nephrology, 2022
- Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review The Permanente Journal, 2021
- Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Heart Failure: A Comprehensive Review of Literature Liaquat National Journal of Primary Care, 2023
- July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities European Journal of Heart Failure, 2023
